INCY Stock Risk & Deep Value Analysis
Incyte Corp
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About INCY Stock
We analyzed Incyte Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran INCY through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
INCY Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk for Incyte is the impending patent expiry for its flagship drug, Jakafi, in 2028. Failure to successfully commercialize a diversified pipeline of new drugs, particularly Opzelura and zilurgisertib, to offset the expected significant revenue decline from generic competition (potentially $1.5B-$2.0B annually from Jakafi) could lead to sustained revenue stagnation or decline.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Medium
Competitive
High
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Jakafi patent cliff scheduled for 2028, posing a major revenue replacement challenge.
- ⚠
Insider disposition of 2,051 shares for ~$200K by Thomas R. Tray on 2026-05-26, though a smaller amount, indicates some selling by an affiliated person.
- ⚠
High reliance on a few key products (Jakafi and Opzelura) means pipeline failures could have an outsized impact on future revenue growth.
Upcoming Risk Events
- 📅
Jakafi Patent Expiry (2028): Introduction of generic ruxolitinib in the US/EU, potentially leading to a significant revenue decline for Incyte, estimated at 30-50% of Jakafi's peak sales, which is currently a substantial portion of overall revenue.
- 📅
Clinical Trial Failure or Regulatory Rejection (Ongoing): Negative results from ongoing Phase 3 trials for key pipeline assets or refusal to approve new drug applications by regulatory bodies (e.g., FDA, EMA) could deplete R&D investment without commercial return.
- 📅
Increased Competition for Opzelura (2027-2028): New or superior topical or systemic treatments for atopic dermatitis or vitiligo entering the market could limit Opzelura's market share growth and pricing power.
When to Reconsider
- 🚪
Exit if quarterly revenue (post-Jakafi patent cliff) drops below $700M for two consecutive quarters, indicating pipeline failure to offset losses.
- 🚪
Sell if any major Phase 3 clinical trial fails to meet primary endpoints or results in a complete response letter (CRL) from the FDA, reducing the probability of a key revenue-generating asset.
- 🚪
Exit if debt-to-equity ratio significantly increases (e.g., above 0.5) due to large acquisitions or unexpected operational losses, compromising financial health.
Unlock INCY Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Incyte Corp (INCY) Do?
Market Cap
$20.80B
Sector
Healthcare
Industry
Biotechnology
Employees
2,617
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Visit Incyte Corp WebsiteInvestment Thesis
If Incyte successfully executes on its diversified pipeline, especially achieving blockbuster status for Opzelura in new indications and securing approvals for new drugs like zilurgisertib, then it can effectively offset the revenue decline from the Jakafi patent cliff post-2028 and sustain annual revenue growth of 8-12%, potentially leading to a P/E multiple expansion as de-risking occurs. This is bullish because the market currently heavily discounts Incyte due to future patent expiries, overlooking the strength and potential of its evolving pipeline.
Is INCY Stock Undervalued?
Unlock the full AI analysis for INCY
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
INCY Price Targets & Strategy
12-Month Target
$125.00
Bull Case
$140.00
Bear Case
$90.00
Valuation Basis
Based on 16.5x forward P/E applied to estimated FY26 EPS of $7.57 (extrapolating Q1 beat and incorporating analyst expectations for full year, adjusted from current TTM ~$6.80 EPS from 14.32 P/E at $102.38).
Entry Strategy
Consider accumulation on dips towards the $95-$100 range, which could represent a consolidation zone after recent Q1 strength. Monitor for technical support levels.
Exit Strategy
Take profit on significant pipeline advancements or if price exceeds the highest analyst target of $135. Stop loss at $90 if key drug readouts are negative or patent cliff concerns intensify.
Portfolio Allocation
3% for moderate risk tolerance due to the stability of a large-cap biopharma, but limited 10x upside.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is INCY Financially Healthy?
Valuation
P/E Ratio
14.53
Profitability
Gross Margin
92.97%
Operating Margin
30.05%
Net Margin
26.71%
Return on Equity
29.20%
Revenue Growth
21.48%
EPS
$7.07
Balance Sheet
Current Ratio
3.32
Quick Ratio
3.04
Debt/Equity
0.01
Other
Beta (Volatility)
0.80
Does INCY Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Eroding (due to Jakafi's impending patent cliff in 2028, but potentially Expanding if pipeline products successfully launch and gain market share)
Moat Sources
3 Identified
The moat's durability beyond 2028 is highly dependent on the successful commercialization and market penetration of its pipeline assets, especially Opzelura and novel compounds. Without new blockbusters, the erosion from Jakafi's patent expiry will be significant.
Moat Erosion Risks
- •Patent expiration and generic competition for flagship product Jakafi after 2028, leading to significant revenue loss.
- •Clinical failures or regulatory setbacks for pipeline drugs, preventing new revenue streams from building.
- •Intense competition from larger pharmaceutical companies with deeper pockets and broader pipelines in oncology and immunology.
INCY Competitive Moat Analysis
Sign up to see competitive advantages
INCY Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral
Institutional Sentiment
Positive (57% Buy, 36.7% Hold from 30 analysts, with a highest price target of $135 after recent Q1 beat).
Insider Activity (Form 4)
Thomas R. Tray (associated with a Form 144) disposed of 2,051 shares for $199,664.85 on 2026-05-26. Proposed disposition of 2,639 shares via stock option exercise on 2026-06-04.
Options Flow
Normal options activity (no specific unusual activity identified in the provided research).
Earnings Intelligence
Next Earnings
Estimated early-August 2026 (for Q2 2026)
Surprise Probability
Medium
Historical Earnings Pattern
Based on the Q1 2026 report, Incyte tends to react positively to EPS and revenue beats, suggesting investor confidence in current operational execution.
Key Metrics to Watch
Competitive Position
Top Competitor
Bristol-Myers Squibb (BMS)
Market Share Trend
Stable in core oncology/hematology segments with Jakafi; Gaining in inflammation/autoimmunity with Opzelura's strong uptake and label extensions.
Valuation vs Peers
Trading at a trailing P/E of 14.32, which is generally in line with or slightly below some large-cap biopharma peers, but typically at a discount to high-growth, clinical-stage biotech companies. This reflects its established nature and patent cliff concerns.
Competitive Advantages
- •Strong R&D capabilities and a diversified pipeline focused on high-need areas.
- •Established commercial infrastructure for successful drug launches and distribution.
- •Proprietary compounds and intellectual property (IP) protecting key drugs like Jakafi (until 2028) and Opzelura.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive INCY Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (Estimated early August 2026): Strong Jakafi and Opzelura sales growth (e.g., >10% YoY) or upward revision of FY26 guidance.
- •ENDO 2026 Presentation of zilurgisertib data (Q3 2026): Positive pivotal late-breaking results for fibrodysplasia ossificans progressiva (FOP) could signal a new significant market opportunity.
- •Updated 24-week long-term data from Phase 3 TRuE-AD4 (H2 2026): Further demonstration of Opzelura's efficacy in atopic dermatitis could support broader adoption and market share gains.
Medium-Term (6-18 months)
- •Phase 3 Pipeline Readouts (2027-2028): Successful pivotal trial results for other key pipeline candidates (e.g., further indications for Opzelura, ruxolitinib, or novel compounds) leading to regulatory submissions.
- •International Expansion of Opzelura (2027): Regulatory approvals and commercial launch in major European or Asian markets for atopic dermatitis and vitiligo, contributing an estimated $100M-$200M in annual incremental revenue.
- •Jakafi Label Extensions & Life Cycle Management (2027-2028): Approval of new indications for Jakafi to extend its market utility and mitigate some patent cliff revenue loss.
Long-Term (18+ months)
- •Successful Diversification Post-Jakafi Patent Cliff (2029+): If Incyte's non-Jakafi pipeline (e.g., Opzelura, zilurgisertib, future oncology assets) collectively replaces a significant portion of Jakafi's revenue post-2028 patent expiry (e.g., 70-80%), the company can maintain revenue stability and grow through new blockbusters to reach $6-8B in annual revenue by 2030.
- •Strategic M&A for Pipeline Enhancement (2028-2030): Acquisition of an innovative early-to-mid-stage biotech with a differentiated asset could significantly augment Incyte's long-term growth profile and market leadership in a new therapeutic area.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for INCY?
- ✓
Watch Opzelura's quarterly sales growth: consistently above 20% YoY would signal strong market penetration and indication expansion.
- ✓
Monitor progress of zilurgisertib: successful Phase 3 results and subsequent regulatory submission in 2027 would indicate a new potential blockbuster asset.
- ✓
Track R&D spending efficiency: declining R&D as a percentage of revenue while maintaining pipeline productivity would indicate improved operational leverage.
Bull Case Analysis
Sign up free to see the bull case
Competing with INCY
See how Incyte Corp compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Incyte Corp INCY | $20.8B | 0.6 | 14.5 | — | 26.7% | 21.5% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Incyte Corp Makes Money
Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology, hematology, and inflammation and autoimmunity. It makes money by selling its approved products, most notably Jakafi (ruxolitinib) for myelofibrosis, polycythemia vera, and graft-versus-host disease, and Opzelura (ruxolitinib cream) for atopic dermatitis and vitiligo. The company also generates revenue through collaborations and licensing agreements for its compounds with other pharmaceutical companies, leveraging its deep research capabilities to develop innovative treatments and bring them to market.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Incyte Corp (INCY)?
As of June 6, 2026, Incyte Corp has a DVR Score of 0.6 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Incyte Corp?
Incyte Corp's market capitalization is approximately $20.8B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Incyte Corp use?
INCY is the ticker symbol for Incyte Corp. The company trades on the NMS.
What is the risk level for INCY stock?
Our analysis rates Incyte Corp's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of INCY?
Incyte Corp currently has a price-to-earnings (P/E) ratio of 14.5. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Incyte Corp's revenue growing?
Incyte Corp has reported revenue growth of 21.5%. The company is showing strong top-line momentum.
Is INCY stock profitable?
Incyte Corp has a profit margin of 26.7%. This indicates strong profitability.
How often is the INCY DVR analysis updated?
Our AI-powered analysis of Incyte Corp is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 6, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for INCY (Incyte Corp) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.